The TGF-β/Smad System in IBD Pathogenesis

Inflammatory Bowel Diseases

Volumn 21, Issue 12, 2015, Pages 2921-2925

  Sedda, Silvia ^a   Marafini, Irene ^a   Dinallo, Vincenzo ^a   Di Fusco, Davide ^a   Monteleone, Giovanni ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

colitis; Crohn's disease; mucosal immunity; Smad7

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MONGERSEN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CROHN DISEASE; CYTOKINE PRODUCTION; EARLY INTERVENTION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IN VIVO STUDY; INFLAMMATORY BOWEL DISEASE; INTESTINE; NONHUMAN; PATHOGENESIS; PATIENT RISK; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; ULCERATIVE COLITIS; UPREGULATION; ANIMAL; COLITIS; IMMUNOLOGY; METABOLISM; MOUSE;

ANIMALS; COLITIS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; MICE; SIGNAL TRANSDUCTION; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 84948167522     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000542     Document Type: Article

References (49)

1. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521-533.
2. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol. 1998;16:137-161.
3. Fantini MC, Becker C, Monteleone G, et al. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25-T cells through Foxp3 induction and down-regulation of Smad7. J Immunol. 2004;172:5149-5153.
4. Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 2006;441: 231-234.
5. Vaday GG, Schor H, Rahat MA, et al. Transforming growth factor beta suppresses tumor necrosis factor alpha-induced matrix metalloproteinase-9 expression in monocytes. J Leukoc Biol. 2001;69:613-621.
6. Burke JP, Mulsow JJ, O'Keane C, et al. Fibrogenesis in Crohn's disease. Am J Gastroenterol. 2007;102:439-448.
7. Ciacci C, Lind SE, Podolsky DK. Transforming growth factor beta regulation of migration in wounded rat intestinal epithelial monolayers. Gastroenterology. 1993;105:93-101.
8. Shi Y, Massague' J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685-700.
9. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997;390: 465-471.
10. Derynck R, Zhang Y, Feng XH. Smads: transcriptional activators of TGF-P responses. Cell. 1998;95:737-740.
11. Abdollah S, Macías-Silva M, Tsukazaki T, et al. TGFPRI phosphorylation of Smad2 on Ser465 and 467 is required for Smad2/Smad4 complex formation and signalling. J Biol Chem. 1997;272:27678-27685.
12. Baker JC, Harland RM. A novel mesoderm inducer, Madr2, functions in the activin signal transduction pathway. Genes Dev. 1996;10:1880-1889.
13. Dennler S, Itoh S, Vivien D, et al. Direct binding of Smad3 and Smad4 to critical TGFP-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 1998;17:3091-3100.
14. Yu L, Hébert MC, Zhang YE. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 2002; 21:3749-3759.
15. Javelaud D, Mauviel A. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene. 2005;24: 5742-5750.
16. Hocevar BA, Brown TL, Howe PH. TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J. 1999;18:1345-1356.
17. Zhang Y, Feng XH, Derynck R. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature. 1998;394: 909-913.
18. Hanafusa H, Ninomiya-Tsuji J, Masuyama N, et al. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-beta-induced gene expression. J Biol Chem. 1999;274: 27161-27167.
19. Sano Y, Harada J, Tashiro S, et al. ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-beta signaling. J Biol Chem. 1999;274:8949-8957.
20. Gorelik L, Flavell RA. Transforming growth factor-P in T-cell biology. Nat Rev Immunol. 2002;2:46-53.
21. Shull MM, Ormsby I, Kier A, et al. Targeted disruption of the murine TGFbeta1 gene results in multifocal inflammatory disease. Nature. 1992; 359:693-699.
22. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 2000;12:171-181.
23. Neurath MF, Fuss I, Kelsall BL, et al. Experimental granulomatous colitis in mice is abrogated by induction of TGF-b-mediated oral tolerance. J Exp Med. 1996;183:2605-2616.
24. Boirivant M, Fuss IJ, Chu A, et al. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med. 1998;188:1929-1939.
25. Powrie F, Carlino J, Leach MW, et al. Critical role for transforming growth factor-P but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RBlow CD4+ T cells. J Exp Med. 1996;183: 2669-2674.
26. Yang X, Letterio JJ, Lechleider RJ, et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-P. EMBO J. 1999;18:1280-1291.
27. Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001;108:601-609.
28. Di Sabatino A, Pickard KM, Rampton D, et al. Blockade of transforming growth factor beta upregulates T-box transcription factor T-bet, and increases T helper cell type 1 cytokine and matrix metalloproteinase-3 production in the human gut mucosa. Gut. 2008;57:605-612.
29. Monteleone G, Mann J, Monteleone I, et al. A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation. J Biol Chem. 2004;279: 3925-3932.
30. Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology. 1996;110:975-984.
31. Fantini MC, Rizzo A, Fina D, et al. Smad7 controls resistance of colito-genic T cells to regulatory T cell-mediated suppression. Gastroenterology. 2009;136:1308-1316.
32. Monteleone G, Del Vecchio Blanco G, Monteleone I, et al. Posttranscrip-tional regulation of Smad7 in the gut of patients with inflammatory bowel disease. Gastroenterology. 2005;129:1420-1429.
33. Kume S, Haneda M, Kanasaki K, et al. SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. J Biol Chem. 2007;282:151-158.
34. Zhang J, Lee SM, Shannon S, et al. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J Clin Invest. 2009;119:3048-3058.
35. Caruso R, Marafini I, Franzè E, et al. Defective expression of Sirt-1 contributes to sustain inflammatory pathways in the gut. Mucosal Immunol. 2014;7:1467-1479.
36. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995;182:1281-1290.
37. Boirivant M, Pallone F, Di Giacinto C, et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology. 2006;131:1786-1798.
38. Rizzo A, Waldner MJ, Stolfi C, et al. Smad7 expression in T cells prevents colitis-associated cancer. Cancer Res. 2011;71:7423-7432.
39. Fina D, Franzè E, Rovedatti L, et al. Interleukin-25 production is differently regulated by TNF-a and TGF-b1 in the human gut. Mucosal Immunol. 2011;4:239-244.
40. Monteleone I, Federici M, Sarra M, et al. Tissue inhibitor of metalloproteinase-3 regulates inflammation in human and mouse intestine. Gastroenterology. 2012;143:1277-1287.
41. Monteleone G, Fantini MC, Onali S, et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol Ther. 2012;20, 870-876.
42. Saruta M, Yu QT, Avanesyan A, et al. Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohn's disease. J Immunol. 2007;178:3293-3300.
43. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331:1286-1292.
44. Di Sabatino A, Jackson CL, Pickard KM, et al. Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut. 2009;58:777-789.
45. Zorzi F, Calabrese E, Monteleone I, et al. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease. Aliment Pharmacol Ther. 2012;36:850-857.
46. Monteleone G, Neurath MF, Ardizzone S, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med. 2015;372:1104-1113.
47. Latella G, Vetuschi A, Sferra R, et al. Smad3 loss confers resistance to the development of trinitrobenzene sulfonic acidinduced colorectal fibrosis. Eur J Clin Invest. 2009;39:145-156.
48. Latella G, Sferra R, Vetuschi A, et al. Prevention of colonic fibrosis by Boswellia and Scutellaria extracts in rats with colitis induced by 2, 4, 5-trinitrobenzene sulphonic acid. Eur J Clin Invest. 2008;38: 410-420.
49. Speca S, Rousseaux C, Dubuquoy C, et al. GED-0507 34 Levo, a novel modulator of PPARgamma as new therapeutic strategy in the treatment of intestinal fibrosis. J Crohns Colitis. 2013;7(suppl 1):S31-S32.